Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?

Li, Yi-Ze; Kong, Shengnan; Liu, Yunpeng; Yang, Yue; Zhang, Hong-Mei

doi:10.3390/jcm12041438

Cited by 8 publications

(3 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell-free DNA (cfDNA) is a crucial genetic component found in the bloodstream; its origin primarily stems from apoptotic, necrotic, and actively secreted fragments originating from healthy, inflamed, and tumour tissue. These fragments are typically approximately 150–180 base pairs in length [ 97 – 99 ]. CtDNA represents a distinctive subset of cfDNA released into the blood by CTCs.…”

Section: Biomarkers and Detection Methodsmentioning

confidence: 99%

Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation

Wang,

Pan

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the most common malignancies. Surgical resection is a potential curative approach for PC, but most patients are unsuitable for operations when at the time of diagnosis. Even with surgery, some patients may still experience tumour metastasis during the operation or shortly after surgery, as precise prognosis evaluation is not always possible. If patients miss the opportunity for surgery and resort to chemotherapy, they may face the challenging issue of chemotherapy resistance. In recent years, liquid biopsy has shown promising prospects in disease diagnosis, treatment monitoring, and prognosis assessment. As a noninvasive detection method, liquid biopsy offers advantages over traditional diagnostic procedures, such as tissue biopsy, in terms of both cost-effectiveness and convenience. The information provided by liquid biopsy helps clinical practitioners understand the molecular mechanisms underlying tumour occurrence and development, enabling the formulation of more precise and personalized treatment decisions for each patient. This review introduces molecular biomarkers and detection methods in liquid biopsy for PC, including circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), noncoding RNAs (ncRNAs), and extracellular vesicles (EVs) or exosomes. Additionally, we summarize the applications of liquid biopsy in the early diagnosis, treatment response, resistance assessment, and prognostic evaluation of PC.

show abstract

Section: Biomarkers and Detection Methodsmentioning

confidence: 99%

Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation

Wang,

Pan

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…Different studies have demonstrated that in ctDNA EGFR mutant patients treated with EGFR TKIs, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) are similar to that in patients with EGFR mutations detected in tumor tissue [ 49 , 50 , 51 , 52 ]. Moreover, mutation status concordance between 652 matched tumor and plasma samples was 94.3%, with a sensitivity of 65.7% and a specificity of 99.8% [ 52 ].…”

Section: Liquid Biopsy Diagnostic’s Application When the Tissue Is Un...mentioning

confidence: 99%

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications

Bertoli

Carlo

Basile

et al. 2023

IJMS

View full text Add to dashboard Cite

Tissue biopsy is essential for NSCLC diagnosis and treatment management. Over the past decades, liquid biopsy has proven to be a powerful tool in clinical oncology, isolating tumor-derived entities from the blood. Liquid biopsy permits several advantages over tissue biopsy: it is non-invasive, and it should provide a better view of tumor heterogeneity, gene alterations, and clonal evolution. Consequentially, liquid biopsy has gained attention as a cancer biomarker tool, with growing clinical applications in NSCLC. In the era of precision medicine based on molecular typing, non-invasive genotyping methods became increasingly important due to the great number of oncogene drivers and the small tissue specimen often available. In our work, we comprehensively reviewed established and emerging applications of liquid biopsy in NSCLC. We made an excursus on laboratory analysis methods and the applications of liquid biopsy either in early or metastatic NSCLC disease settings. We deeply reviewed current data and future perspectives regarding screening, minimal residual disease, micrometastasis detection, and their implication in adjuvant and neoadjuvant therapy management. Moreover, we reviewed liquid biopsy diagnostic utility in the absence of tissue biopsy and its role in monitoring treatment response and emerging resistance in metastatic NSCLC treated with target therapy and immuno-therapy.

show abstract

“…Indeed, liquid biopsy kits for oncogenic driver mutations, such as those of EGFR and ALK , have already been approved for clinical use [ 8 ]. ctDNA/cfDNA analysis is applied for the screening of therapeutic targets, to unveil drug resistance mechanisms, and the monitoring of minimal residual disease (MRD) in non-small-cell lung cancer (NSCLC) with the EGFR mutation [ 9 ]. After lung cancer, prostate cancer is the second-most-frequent malignancy in men worldwide.…”

mentioning

confidence: 99%